We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-1.62%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.99B
AUM Growth
-$546M
Cap. Flow
-$71.8M
Cap. Flow %
-2.4%
Top 10 Hldgs %
48.59%
Holding
90
New
10
Increased
29
Reduced
22
Closed
16

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$131M
2
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$75.7M
3
IGMS
IGM Biosciences
IGMS
+$63.5M
4
ALLK
Allakos
ALLK
+$51.3M
5
NVRO
NEVRO CORP.
NVRO
+$48.5M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$405M
2
EHTH icon
eHealth
EHTH
+$76.5M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$62.6M
4
ELV icon
Elevance Health
ELV
+$51.8M
5
UNH icon
UnitedHealth
UNH
+$34M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Miscellaneous 0.93%
3 Energy 0.01%
4 Technology 0%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FTSV
51
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$10.4M 0.35%
1,627,498
+1,393,498
+596% +$11.4M
VAPO
52
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$9.09M 0.3%
119,942
– –
GTHX
53
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$8.9M 0.3%
390,934
+98,200
+34% +$3.1M
CBIO
54
Crescent Biopharma
CBIO
$659M
$8.61M 0.29%
19,976
-108
-0.5% -$69.5K
LOGC
55
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$8.1M 0.27%
749,026
-65,872
-8% -$705K
CMRX
56
DELISTED
Chimerix, Inc.
CMRX
$7.6M 0.25%
3,235,795
-322,593
-9% -$931K
SDC
57
DELISTED
SmileDirectClub, Inc. Class A Common Stock
SDC
$6.81M 0.23%
+490,340
New +$8.18M
GOSS icon
58
Gossamer Bio
GOSS
$83.2M
$4.37M 0.15%
260,500
+11,900
+5% +$237K
HZNP
59
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$400K 0.01%
14,700
+3,300
+29% +$85.3K
OVID icon
60
Ovid Therapeutics
OVID
$547M
$395K 0.01%
121,950
-615,600
-83% -$1.4M
MYOK
61
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$375K 0.01%
7,182
+930
+15% +$49.5K
ELGX
62
DELISTED
Endologix Inc
ELGX
$313K 0.01%
78,755
– –
AMED
63
DELISTED
Amedisys
AMED
$304K 0.01%
2,320
– –
FLXN
64
DELISTED
Flexion Therapeutics, Inc.
FLXN
$296K 0.01%
21,630
– –
VCEL icon
65
Vericel Corp
VCEL
$2.1B
$253K 0.01%
16,720
– –
NBIX icon
66
Neurocrine Biosciences
NBIX
$15.7B
$247K 0.01%
2,740
– –
LHCG
67
DELISTED
LHC Group LLC
LHCG
$246K 0.01%
2,166
– –
INSP icon
68
Inspire Medical Systems
INSP
$1.78B
$239K 0.01%
+3,910
New +$257K
BCRX icon
69
BioCryst Pharmaceuticals
BCRX
$2.51B
$215K 0.01%
+75,000
New +$233K
UNH icon
70
UnitedHealth
UNH
$353B
$211K 0.01%
971
-140,930
-99% -$34M
ESTA icon
71
Establishment Labs
ESTA
$2.11B
$189K 0.01%
10,000
– –
VKTX icon
72
Viking Therapeutics
VKTX
$3.75B
$112K ﹤0.01%
16,260
– –
CSLT
73
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
$14K ﹤0.01%
10,229
– –
ADVM
74
DELISTED
Adverum Biotechnologies
ADVM
– –
-2,224
Closed -$264K
BMRN icon
75
CALL
BioMarin Pharmaceuticals
BMRN
$12.5B
– –
-100,000
Closed -$8.56M
1 2
3
4

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q3 2019 Portfolio in Review

As of Q3 2019, Redmile Group held 90 positions worth $2.99B, down 15% from $3.53B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Redmile Group's Q3 2019 filing shows 10 new, 29 increased, 22 reduced and 16 closed positions. Its largest new stake was Alexion Pharmaceuticals: 1,162,200 shares worth $114M. The largest sale was Array Biopharma Inc, an estimated $405M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 96% a quarter earlier, followed by Miscellaneous and Energy.

  • Redmile Group's largest Q3 2019 buy was Alexion Pharmaceuticals: 1,162,200 shares worth $114M.
  • Redmile Group added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2019, an estimated $75.7M increase.
  • Redmile Group's biggest Q3 2019 reduction was UnitedHealth, cutting an estimated $34M.
  • Redmile Group fully exited Array Biopharma Inc in Q3 2019, selling an estimated $405M.
  • Redmile Group's ten largest holdings make up 49% of its $2.99B portfolio in Q3 2019.
  • Redmile Group opened 10 new positions and closed 16 in Q3 2019.
  • Redmile Group's portfolio value fell 15% quarter-over-quarter to $2.99B.

Based on Redmile Group's 13F filing for Q3 2019, filed 14 Nov 2019.